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tober 7, 2013.e evaluated the feasibility and safety of epicardial substrate elimination with endocardial radiofrequency
(RF) delivery in patients with scar-related ventricular tachycardia (VT).Background Epicardial RF delivery is limited by fat or associated with bleeding, extra-cardiac damages, coronary vessels
and phrenic nerve injury. Alternative ablation approaches might be desirable.Methods Forty-six patients (18 ischemic cardiomyopathy [ICM], 13 nonischemic dilated cardiomyopathy [NICM], 15
arrhythmogenic right ventricular cardiomyopathy [ARVC]) with sustained VT underwent combined endo- and
epicardial mapping. All patients received endocardial ablation targeting local abnormal ventricular activities in
the endocardium (Endo-LAVA) and epicardium (Epi-LAVA), followed by epicardial ablation if needed.Results From a total of 173 endocardial ablations targeting Epi-LAVA at the facing site, 48 (28%) applications (ICM: 20 of 71
[28%], NICM: 3 of 39 [8%], ARVC: 25 of 63 [40%]) successfully eliminated the Epi-LAVA. Presence of Endo-LAVA, the
most delayed and low bipolar amplitude of Epi-LAVA, low unipolar amplitude in the facing endocardium, and
Epi-LAVA within a wall thinning area at computed tomography scan were associated with successful ablation.
Endocardial ablation could abolish all Epi-LAVA in 4 ICM and 2 ARVC patients, whereas all patients with NICM
required epicardial ablation. Endocardial ablation was able to eliminate Epi-LAVA at least partially in 15 (83%) ICM,
2 (13%) NICM, and 11 (73%) ARVC patients, contributing to a potential reduction in epicardial RF applications.
Pericardial bleeding occurred in 4 patients with epicardial ablation.Conclusions Elimination of Epi-LAVA with endocardial RF delivery is feasible and might be used ﬁrst to reduce the risk of epicardial
ablation. (J Am Coll Cardiol 2014;63:1416–26) ª 2014 by the American College of Cardiology FoundationSince the ﬁrst description of epicardial ventricular tachy-
cardia (VT) ablation with percutaneous subxiphoid access in
1996 (1), epicardial mapping and ablation have been widely
performed for the treatment of scar-related VT. CombinedElectrophysiology, Hôpital Cardiologique du
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revised manuscript received September 3, 2013,endo- and epicardial ablation has been used to achieve
improved outcomes, not only in the setting of nonischemic
dilated cardiomyopathy (NICM) (2,3) and arrhythmogenic
right ventricular cardiomyopathy (ARVC) (4–6), but also in
ischemic cardiomyopathy (ICM) (7,8). Regions of critically
slow conduction necessary for re-entry can lie deep in the
subendocardial layer or in the epicardial myocardium, and
can be recorded as local abnormal ventricular activities
(LAVA) from the pericardial space. Complete elimination
of both endocardial (Endo-LAVA) and epicardial local
abnormal ventricular activities (Epi-LAVA), if present, is
associated with superior survival from recurrent VT during
long-term follow-up (9).
Endocardial ablation is usually effective in eliminating
most endocardial substrates, but epicardial lesions are
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1417thought to be required for epicardial targets. Epicardial
radiofrequency (RF) ablation has potential risks, however,
such as pericardial bleeding and injury of coronary vessels or
the phrenic nerve (10–12). Epicardial ablation, particularly if
contact force is not directed toward the heart, can result in
extra-cardiac damage such as pulmonary lesions (13).
Furthermore, epicardial fat can signiﬁcantly reduce ablation
lesion depth (14). One-fourth of the epicardial surface
is covered by >4 mm of fat, which is predominantly present
at the left ventricular (LV) superior wall and right ventricular
(RV) anterior wall (15). An epicardial fat layer >7 mm and
substrate in close proximity to the coronary arteries are
associated with epicardial ablation failure (15), highlighting
the need for alternative ablation approaches.See page 1427
computed tomography
NICM = nonischemic dilated
cardiomyopathy
RF = radiofrequency
RV = right ventricle/
ventricular
VT = ventricular tachycardia
3D = 3-dimensionalThe objective of this study was to evaluate the feasibility
and safety of Epi-LAVA elimination with endocardial RF
delivery in patients with scar-related VT as a result of
ICM, NICM, and ARVC. The secondary objective was to
assess variables that might be predictive of successful Epi-
LAVA elimination endocardially, including clinical and
electrophysiological parameters and anatomic information as
assessed by contrast-enhanced multidetector computed
tomography (MDCT).Methods
Patient selection. This study enrolled consecutive patients
who underwent combined endo- and epicardial mapping/
ablation of scar-related sustained VT with a 3-dimensional
(3D) electroanatomic mapping system between April 2009
and March 2013 at our center. All patients had episodes
of repetitive sustained VT, resistant to antiarrhythmic drug
therapy, requiring external cardioversion or therapy from
an implantable cardioverter-deﬁbrillator (ICD). Ischemic
cardiomyopathy was diagnosed on the basis of signiﬁcant
coronary artery disease (>75% stenosis), documented
myocardial infarction, and/or Q waves in the 12-lead elec-
trocardiogram with regional wall motion abnormality. The
diagnosis of NICM was based on a LV ejection fraction
of <50% in the absence of coronary artery disease, docu-
mented myocardial infarction, or focal wall motion abnor-
mality. Patients diagnosed as ARVC fulﬁlled 2010 task force
criteria (16). We excluded other causes of sustained VT,
such as cardiac sarcoidosis, congenital heart disease, long-
lasting hypertensive heart disease, valvular heart disease,
and toxin-related cardiomyopathy. Written informed con-
sent was obtained from all patients.
Electrophysiological study. All anti-arrhythmic drugs
except amiodarone were discontinued for at least 5 half-lives
before ablation if the stability of arrhythmia allowed it. The
ICD therapies were turned off, and the device was pro-
grammed to a surveillance-only mode. A 6-F steerable
quadripolar or decapolar catheter (Xtrem, ELA Medical,Montrouge, France; or Dynamic,
BARD Electrophysiology, Low-
ell, Massachusetts) was inserted
from the right femoral vein
and placed into the distal coro-
nary sinus or at the RV apex. The
LV endocardium was accessed by
transseptal or retrograde trans-
aortic approach. Pericardial access
was obtained through a subxiphoid
and anterior puncture under left
lateral ﬂuoroscopic guidance in
all patients. The indications for
epicardial access were previous
failed endocardial ablation, mini-
mal or no endocardial scar, sus-
pected epicardial substrate on the
basis of VT morphology (17,18),
or the type of cardiomyopathy
(NICM and ARVC). A steerable
sheath (Agilis, St. Jude Medical,
St. Paul, Minnesota) was intro-
duced into the pericardial space.
Continuous aspiration was then connected to the sheath.
Systemic heparinization was maintained throughout the pro-
cedure with a target activated clotting time 200 s after
establishment of pericardial access and transseptal puncture.
Both endo- and epicardial mapping were performed with a
multipolar high-densitymapping catheter (PentaRay, Biosense
Webster, Diamond Bar, California) in all patients. Although
PentaRay allows high-density mapping in both endo- and
epicardium, it may produce mechanical ectopics when used
endocardially. In this situation, we used a 4-mm-tip mapping
catheter (Navistar-Thermocool, Biosense Webster) to com-
plete mapping. Electrograms were ﬁltered at 30 to 250 Hz
(bipolar) and 1 to 240 Hz (unipolar). Electroanatomic map-
ping was performed during sinus rhythmwith Carto (Biosense
Webster) or NavX (St. Jude Medical).
MDCT image processing and registration. Our strategy
for MDCT image acquisition and registration with the 3D
electroanatomic map is provided in the Online Appendix
and is as previously described (19). Contrast-enhanced
MDCT was performed on a 64-slice computed tomogra-
phy scanner (SOMATOM Deﬁnition, Siemens Medical
Solutions, Forchheim, Germany) 1 to 3 days before the
procedure in 21 patients. Three-dimensional surface meshes
of the endocardium, epicardium, coronary arteries, coronary
sinus, and LV myocardial wall thinning (deﬁned as areas
with end-diastolic wall thickness <5 mm) were generated
from MDCT data with CardioviZ3D software (INRIA,
Sophia Antipolis, France). A cutoff of 5 mm for signiﬁcant
LV wall thinning was based on a previous report describing
the reference values of wall thicknesses by MDCT in a
healthy population (20). The MDCT data were imported
into 3D navigation systems and integrated with the elec-
troanatomic maps. Whether Epi-LAVA were located inside
Figure 1 Endocardial Ablation Eliminates Epicardial LAVA at Facing Site in Patient With ICM
(A) The multielectrode catheter (PentaRayNav) lying epicardially displayed local abnormal ventricular activities (LAVA) (*). Endocardial (Endo) ablation catheter placed at the
facing site to the epicardial (Epi) PentaRayNav by a transseptal approach also showed abnormal sharp signals. (B) Endocardial ablation eliminated Epi-LAVA after increasing
their delay. dist ¼ distal; RF ¼ radiofrequency.
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assessed.
Deﬁnition of LAVA and low-voltage zone. As previously
described (9,21), LAVA were deﬁned as electrograms from
poorly coupled surviving myocardial ﬁbers with the
following features: 1) sharp, high-frequency ventricular po-
tentials distinct from the far-ﬁeld ventricular electrogram;
2) occurring anytime during or, more frequently, after thefar-ﬁeld ventricular electrogram during sinus rhythm; and
3) sometimes displaying double or multiple high-frequency
signals separated by very low-amplitude signals or an iso-
electric interval. When LAVA occur within the QRS and
are fused with the far-ﬁeld ventricular potential, ventricular
pacing with extrasystole is performed to differentiate them
from the far-ﬁeld ventricular potential. The LAVA are
delayed and distinguished from the far-ﬁeld potential by the
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bundle generating the LAVA signal.
We employed the following voltage criteria: a peak-
to-peak bipolar amplitude of <1.5 mV deﬁned the bipolar
low-voltage zone (22); and a unipolar amplitude of <8.3 mV
in the LV and <5.5 mV in the RV deﬁned the low unipolar
voltage zone (23,24).
RF ablation. After completion of endo- and epicardial
mapping, VT inducibility was tested by programmed ven-
tricular stimulation from the RV apex at a basic drive cycle
length of 600 and 400 ms with up to triple extrastimulae
decrementally to 200 ms or ventricular refractoriness. When
hemodynamically tolerated VT was inducible, ablation was
guided by conventional activation and entrainment mapping
(25). The critical sites of VT were deﬁned as the sites where
pre-systolic or mid-diastolic electrograms were present and
either RF ablation or mechanical manipulation by the
catheter terminated the VT, followed by noninducibility of
the VT that was reproducibly inducible before. After
termination of VT, further ablation targeting LAVA during
sinus rhythm was performed. In patients with noninducible
or poorly tolerated VT, ablation of LAVA was performed in
sinus rhythm. Radiofrequency energy was delivered with a
3.5-mm open-irrigation catheter (NaviStar-Thermocool,
Biosense Webster) with a power of 30 to 50 W endo-
cardially. When ablating epicardially or in the RV endo-
cardium, power ranged from 25 to 35 W.
If LAVA were detected on both the endo- and epicar-
dium, our strategy was always to start ablation endocardially,
aiming at elimination of both Endo- and Epi-LAVA. If
LAVA were detected epicardially in the absence of Endo-
LAVA, endocardial ablation was performed at the facing
site aiming to abolish the potentials transmurally. During
endocardial ablation at the facing site of Epi-LAVA, careful
monitoring of transmural response and elimination of Epi-
LAVA was possible with a multipolar high-density map-
ping catheter (PentaRay, Biosense Webster), which was
placed at Epi-LAVA sites and stabilized by a steerable
sheath (Agilis, St. Jude Medical) (Fig. 1). This strategy was
repeated at adjacent sites as needed to achieve complete
Epi-LAVA elimination. After endocardial ablation, epicar-
dial mapping of areas previously displaying LAVA was
performed and used to guide further ablation as indicated by
Epi-LAVA persistence. Remapping allowed us to classify
patients as having complete or incomplete Epi-LAVA
elimination after endocardial ablation.
The goal and ideal procedural endpoint was complete
elimination of all identiﬁed LAVA. Induction of VT was
repeated with programmed stimulation with the same pro-
tocol as pre-ablation. In hemodynamically unstable patients,
VT inducibility was not retested post-ablation.
Follow-up. After ablation, ICD therapies were reprog-
rammed with active VT and ventricular ﬁbrillation zones.
Patients were monitored at least 48 h in-hospital before
discharge. Patients were followed every 3 months to assess
VT recurrences. Recurrence of VT after hospital dischargewas assessed by ICD interrogation at each visit and by
careful interview, electrocardiogram, and a Holter moni-
toring for the patients without ICD. Any sustained VT
during follow-up, whether symptomatic or treated by ICD
or not, was considered a recurrence of VT.
Statistical analysis. Categorical variables were expressed
as numbers and percentages, and were compared with
Pearson chi-square test or Fisher exact test, as appropriate.
Continuous data for normally distributed variables were
expressed as mean  SD and compared by Student t
test. Non-normally distributed variables were expressed as
median (25th, 75th percentiles) and compared with Mann-
Whitney U test or Kruskal-Wallis test. No corrections
were made for multiple observations within individuals.
Statistical calculations were performed with SPSS (version
21.0, IBM, SPSS, Chicago, Illinois). All tests were
2-tailed, and a p value of <0.05 was considered statistically
signiﬁcant.Results
Study population. During the study period, a total of 51
patients (20 ICM, 15 NICM, 16 ARVC) underwent
combined endo- and epicardial mapping with a 3D navi-
gation system. The 46 (18 ICM, 13 NICM, 15 ARVC)
patients who demonstrated evidence of Epi-LAVA
comprised this study cohort (Table 1). Four patients had
previously failed ablation (range 1 to 3). No patient had
previous cardiac surgery. Pericardial access was obtained
percutaneously in all. For LV endocardial access (ICM
and NICM patients), a retrograde approach was used in
7 patients, and a transseptal approach was used in 24
patients.
Prevalence of abnormal regions. Endo- and epicardium
were mapped with 420  271 and 572  379 points/map,
respectively. In ICM and NICM, the locations of epicardial
low-voltage regions (bipolar voltage <1.5 mV) with pres-
ence of Epi-LAVA were the following: the apex in 15 (13
ICM, 2 NICM); anterior in 13 (10 ICM, 3 NICM);
inferior in 15 (8 ICM, 7 NICM); and lateral in 18 (5 ICM,
13 NICM). In ARVC, epicardial low-voltage regions with
Epi-LAVA were identiﬁed apically in 3, anteriorly in 9,
inferiorly in 9, and laterally in 11. An endocardial low-
voltage area was identiﬁed in all (100%) patients with
ICM, 9 (69%) patients with NICM, and 13 (87%) patients
with ARVC. The endo- and epicardial bipolar low-voltage
area was 80.2 (62.9, 124.3) cm2 and 77.7 (45.4, 111.4)
cm2 in ICM; 11.7 (3.2, 29.6) cm2 and 45.2 (39.2, 53.6) cm2
in NICM; and 32.5 (11.1, 55.7) cm2 and 110.6 (55.0,
139.0) cm2 in ARVC. Contrast-enhanced MDCT was
performed in 21 patients (12 ICM and 9 NICM). A wall
thinning region was identiﬁed in all ICM and 7 NICM
patients. In all patients, high-resolution wall thinning seg-
mentation was successfully integrated with 3D electro-
anatomic mapping, and its location corresponded to the
electrophysiological scar.
Table 1 Characteristics of the Study Population
Age, yrs 52  16
Male/female 42/4
Underlying structural heart disease
ICM 18
NICM 13
ARVC 15
Hypertension 18 (39%)
LV ejection fraction 38  14
ICD 41 (89%)
NYHA III 5 (11%)
Medications
Amiodarone 36 (78%)
Beta-blocker 43 (93%)
Prior failed ablation procedure 4 (9%)
VT morphology, n 2.0 (1.0, 3.0)
Values are mean  SD, median (quartiles), or n (%), unless otherwise indicated.
ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; ICD ¼ implantable cardioverter-
deﬁbrillator; ICM ¼ ischemic cardiomyopathy; LV ¼ left ventricular; NICM ¼ nonischemic dilated
cardiomyopathy; NYHA ¼ New York Heart Association; VT ¼ ventricular tachycardia.
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There was no signiﬁcant artifactual interference on the
multielectrode catheter placed on the epicardium during
ablation from the endocardial site, which enabled moni-
toring of the transmural response in the target Epi-LAVA
(Fig. 1). A total of 173 endocardial ablations of Epi-
LAVA monitored by multielectrode catheter during the
RF energy delivery were analyzed. Of these, 79 (46%) were
targeted from sites with no Endo-LAVA. Among 173 Epi-
LAVA sites, 48 (28%) applications successfully eliminated
the facing Epi-LAVA. Successful ablation was most
frequently achieved in ARVC (25 of 63 applications [40%]),
followed by ICM (20 of 71 applications [28%]). In NICM,
only 3 of 39 applications (8%) successfully eliminated the
Epi-LAVA at the facing site. Figure 2 shows Epi-LAVA
and VT re-entry circuit eliminated by ablation at the fac-
ing endocardial site in a patient with ARVC. In total, 39
VTs (18 in ICM, 9 in NICM, 12 in ARVC) were hemo-
dynamically tolerated and mapped with conventional acti-
vation and entrainment mapping approaches. Of these, 23
(7 in ICM, 7 in NICM, 9 in ARVC) VTs had the critical
site of VT re-entrant circuit identiﬁed in the epicardium.
Endocardial ablation at the facing site of the epicardial
critical isthmus was performed, leading to successful termi-
nation of 5 VTs (2 [28%] ICM, 0 [0%] NICM, 3 [33%]
ARVC).
Table 2 shows predictors of successful Epi-LAVA elim-
ination endocardially. There were no signiﬁcant differences
in RF time, average temperature, average impedance, and
power between successful and unsuccessful ablation. Endo-
LAVA at the ablation site was more frequently present in
the success site (32 of 48 [67%] vs. 62 of 125 [50%],
p ¼ 0.044). The most delayed Epi-LAVA were more
frequently eliminated; that is, the duration from the onset
of ventricular electrogram to the end of Epi-LAVA(electrogram-duration) was signiﬁcantly longer in the suc-
cessful site than unsuccessful sites (143 [116, 186] ms vs.
110 [86, 140] ms, p < 0.001). Bipolar amplitude of Epi-
LAVA was signiﬁcantly lower at successful ablation sites
(0.26 [0.21, 0.34] mV vs. 0.71 [0.34, 1.24] mV,
p < 0.001). Bipolar and unipolar amplitude of the facing
endocardial ablation site was also lower at successful ablation
sites (0.35 [0.21, 0.61] mV vs. 0.54 [0.22, 1.03] mV,
p¼ 0.041; and 2.52 [2.02, 2.96] mV vs. 4.51 [3.38, 5.51] mV,
p < 0.001, respectively).
The relationship between the impact of endocardial abla-
tion on Epi-LAVA at the facing site and LV wall thinning
seen on MDCT was assessed in 95 RF applications in the
21 patients. Of these, 72 (76%) Epi-LAVA (ICM: 59 of
67 [88%], NICM: 13 of 28 [46%]) were located within the
wall thinning area, and the remaining 23 were outside.
None of the 23 Epi-LAVA outside the wall thinning seg-
mentation could be eliminated transmurally from the endo-
cardium, whereas 23 (32%) of 72 Epi-LAVA within the wall
thinning could be eliminated (p ¼ 0.002).
Overall outcome of endocardial ablation of Epi-LAVA.
In 4 of 18 patients with ICM and 2 of 15 patients with
ARVC, endocardial ablation could abolish all Epi-LAVA.
These patients achieved complete elimination of both
Endo- and Epi-LAVA with only endocardial ablation. By
contrast, all patients with NICM required epicardial abla-
tion. Incomplete Epi-LAVA elimination after endocardial
ablation occurred in 22 patients (11 ICM, 2 NICM, 9
ARVC). Therefore, endocardial ablation had an impact on
Epi-LAVA in 15 (83%) ICM, 2 (13%) NICM, and 11
(73%) ARVC patients, contributing to a potential reduction
in epicardial RF applications.
Table 3 shows the characteristics of patients with com-
plete, partial, and no elimination of Epi-LAVA by endo-
cardial ablation. Patients with no impact of endocardial
ablation on Epi-LAVA had the smallest low-voltage area in
both endo- and epicardium. The presence of Endo-LAVA
was associated with a greater impact of endocardial abla-
tion on Epi-LAVA. In all patients with complete elimina-
tion of Epi-LAVA endocardially (6 of 6 [100%]) and most
patients with partial elimination (15 of 22 [68%]), all Epi-
LAVA corresponded with low endocardial unipolar
voltage, compared with 3 of 18 (17%) patients with no
elimination.
In 8 (7 ICM and 1 NICM) of 21 patients undergoing
MDCT, all identiﬁed Epi-LAVA were located within the
LV wall thinning segmentation. In all of these, endocardial
ablation had an impact on Epi-LAVA (complete elimi-
nation in 2, and partial elimination in 6). The remaining
13 patients had presence of Epi-LAVA that were located
outside the wall thinning (Fig. 3). None of these attained
complete elimination of Epi-LAVA endocardially; 4 had
partial impact of endocardial ablation on Epi-LAVA, and
9 had no impact.
Procedural and follow-up results. Mean procedure and
RF time were 310  65 min and 34  14 min, respectively.
Figure 2 Epi VT Re-Entry Circuit Eliminated by Ablation at Facing Endo Site in Patient With ARVC
(A) Ventricular tachycardia (VT) that was hemodynamically tolerated was mapped in both endo- and epicardium in an arrhythmogenic right ventricular cardiomyopathy (ARVC)
patient. The isochronal map during VT showed the critical isthmus of the VT reentrant circuit at the Epi basal postero-lateral region. The local electrograms at the critical isthmus
displayed fractionated signals covering almost the entire cycle length of the VT (a,b,c,d). However, the critical isthmus was close to the right coronary artery rendering RF
ablation at the region unwarranted. (B) The multielectrode catheter (PentaRayNav) was placed at the Epi slow conducting region. The ablation catheter was put at the Endo
region facing the Epi PentaRayNav. (C) The Epi PentaRayNav displayed fractionated pre-systolic potentials, whereas the Endo ablation catheter showed fewer fractionated
potentials activating later, compared with the fractionated signals at the facing Epi site. (D) Radiofrequency energy application on the Endo region terminated the VT after
prolongation of VT cycle length. (E) After termination of VT, LAVA were identiﬁed at the Epi critical isthmus of the VT re-entrant circuit (*). Endo ablation at the facing site was
continued in sinus rhythm and eliminated the Epi LAVA completely. Abbreviations as in Figure 1.
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Table 2 Predictor of Successful Epi-LAVA Elimination From Ablation at Facing Endo Site
Success
(n ¼ 48)
Failure
(n ¼ 125) p Value
RF parameters
RF time, s 68 (56, 88) 65 (55, 87) 0.60
Average temperature, C 38 (36, 40) 39 (37, 40) 0.36
Average impedance, U 140 (130, 155) 143 (130, 165) 0.25
Power, W 35 (30, 36) 35 (30, 38) 0.37
Electrophysiological parameters
Presence of opposite Endo-LAVA 32 (67%) 62 (50%) 0.044
Electrogram-duration of the target Epi-LAVA, ms 143 (116, 186) 110 (86, 140) <0.001
Electrogram-duration of opposite Endo-LAVA, ms 110 (96, 131) 114 (95, 138) 0.66
Bipolar amplitude of the target Epi-LAVA, mV 0.26 (0.21, 0.34) 0.71 (0.34, 1.24) <0.001
Bipolar amplitude of opposite endocardium, mV 0.35 (0.21, 0.61) 0.54 (0.22, 1.03) 0.041
Unipolar amplitude of opposite endocardium, mV 2.52 (2.02, 2.96) 4.51 (3.38, 5.51) <0.001
Values are median (quartiles) or n (%).
Endo ¼ endocardial; Epi ¼ epicardial; LAVA ¼ local abnormal ventricular activities; RF ¼ radiofrequency.
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identiﬁed LAVA were completely eliminated in 32 (70%)
patients (13 of 18 [72%] ICM, 7 of 13 [54%] NICM, 12 of
15 [80%] ARVC). As shown in Figure 4, complete elimi-
nation of all Endo- and Epi-LAVA was more likely to be
achieved in patients with impact of endocardial ablation on
Epi-LAVA than those without (23 of 28 [72%] vs. 9 of
18 [50%], p ¼ 0.021). In 14 patients, complete elimination
of LAVA could not be achieved. Of these, 6 (1 ICM,
4 NICM, 1 ARVC) patients had epicardial LAVA that
were located close to the coronary arteries or phrenic nerve.
In the remaining 8 patients, LAVA could not be abolished,
despite extensive ablation. Pericardial bleeding occurred in
4 patients. Three of them were managed conservatively, but
1 patient required surgical intervention. Pericardial bleedingTable 3 Patients With Complete, Partial, and No Elimination of Epi-L
Complete Elimination of
Epi-LAVA Endocardially
(n ¼ 6)
Age, yrs 56  15
Male 6 (100%)
LV ejection fraction 36  17
Medications
Amiodarone 5 (83%)
Beta-blocker 6 (100%)
Underlying structural heart disease
ICM 4 (67%)
NICM 0 (0%)
ARVC 2 (33%)
VT morphology, n 1.5 (0.8, 4.0)
Endo total low-voltage area, cm2 65.0 (47.5, 107.8)
Epi total low-voltage area, cm2 97.9 (43.3, 120.2)
Presence of Endo-LAVA 6 (100%)
Amplitude of Epi-LAVA, mV 0.37 (0.33, 0.45)
Duration of Epi-LAVA, ms 156 (121,195)
All Epi-LAVA within abnormal
Endo unipolar voltage zone
6 (100%)
Values are mean  SD, median (quartiles), or n (%).
Abbreviations as in Tables 1 and 2.only occurred in patients who received epicardial RF de-
livery. There was no phrenic nerve palsy, injury of coronary
vessels, hepatic injury, or intra-abdominal bleeding.
One patient with ICM died of severe heart failure with
recurrence of VT storm 48 h after the ablation procedure.
One patient with ICM died of a noncardiac cause 5 months
after the intervention. After a median follow-up period of
11 months, 31 (67%) patients were free from both death and
VT recurrence. Patients who achieved complete elimination
of Endo- and Epi-LAVA were more frequently free
from VT recurrence and death (25 of 32 [78%] vs. 6 of 14
[43%], p ¼ 0.024). Of 6 patients in whom endocardial
ablation abolished all Epi-LAVA, 5 patients were free from
VT recurrence and death, and 1 patient experienced VT
recurrence. Three patients underwent redo procedures, 2AVA Endocardially
Partial Elimination of
Epi-LAVA Endocardially
(n ¼ 22)
No Impact of Endo
Ablation on Epi-LAVA
(n ¼ 18) p Value
53  16 50  16 0.65
19 (86%) 17 (94%) 0.63
39  16 38  9 0.86
17 (77%) 13 (72%) 0.38
20 (91%) 17 (94%) 0.61
11 (50%) 3 (17%) 0.002
2 (9%) 11 (61%)
9 (41%) 4 (22%)
1.5 (0, 3.0) 2.0 (1.0, 2.3) 0.82
59.1 (40.4, 86.7) 12.6 (5.1, 40.1) 0.010
101.0 (49.4, 117.8) 47.6 (39.8, 68.0) 0.030
18 (82%) 7 (39%) 0.003
0.39 (0.24, 0.74) 0.67 (0.43, 1.31) 0.041
139 (116, 163) 108 (90, 149) 0.044
15 (68%) 3 (17%) <0.001
Figure 3 Endo and Epi Voltage Map With Wall Thinning Segmentation in Patient With ICM
(A) Endo bipolar voltage map shows low voltage with the presence of LAVA (light blue dots) at the basal postero-lateral left ventricle. A peak-to-peak bipolar amplitude <1.5 mV
is deﬁned as low voltage, and <0.5 mV is deﬁned as dense scar. (B) Endo unipolar voltage map is shown. A unipolar amplitude of <8.3 mV is deﬁned as abnormal voltage.
(C) Epi bipolar voltage map merged with the multidetector computed tomography model shows the location of low-voltage area and LAVA corresponding to the wall thinning
segmentation (white area). Endo ablation successfully eliminated the posterolateral LAVA (in blue box), which had the following characteristics: low bipolar amplitude; location
within the wall thinning segmentation; opposite Endo low unipolar voltage; and presence of LAVA at the opposite endocardium. On the contrary, Epi LAVA located mid-anteriorly
(in red box) could not be eliminated by Endo ablation and needed to be ablated epicardially. They were of higher bipolar voltage (>1.5 mV), located outside the wall thinning
segmentation, and opposite endocardium with higher unipolar amplitude. Abbreviations as in Figure 1.
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1423of whom had LAVA successfully eliminated during the
initial procedure, and the other had persistent LAVA. The
repeat epicardial procedure with percutaneous subxiphoid
access was successfully performed in all patients. Both pa-
tients who achieved complete LAVA elimination at the
index procedure had LAVA recovery. Repeat ablation
eliminated all LAVA.Discussion
This study describes the feasibility and safety of a novel
approach for modiﬁcation of subepicardial VT substrate
from endocardial ablation and demonstrates the following:
1. Endocardial RF was associated with Epi-LAVA
elimination at the facing site in 28% of applications,
Figure 4 Patient Flow Chart and Procedure Outcome
Abbreviations as in Figure 1.
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1424and complete or incomplete elimination was achieved
in 61% of patients overall, thereby reducing the need
for epicardial ablation.
2. The underlying structural heart disease was a major
determinant of success, because only 8% of endocar-
dial applications eliminated the facing Epi-LAVA in
NICM, compared with 28% in ICM and 40% in
ARVC.
3. The electrophysiological characteristics of the targeted
region were also important; the most delayed and
lowest bipolar amplitude Epi-LAVA were more prone
to complete elimination. Similarly low unipolar
amplitude in the facing endocardium was associated
with greater success.
4. Endocardial ablation was more likely to eliminate
epicardial substrate when delivered in a thin-walled
region of the LV (<5 mm at MDCT).
These ﬁndings indicate that epicardial scar homogeniza-
tion by complete elimination of poorly coupled bundles
through endocardial ablation is more readily achieved within
the most severe scars.
Elimination of epicardial LAVA by endocardial transmural
lesion. Recurrent VT originating from the subepicardium
is thought to be an important reason for failure of endo-
cardial ablation (26–30). Elimination of epicardial
arrhythmia substrate with endocardial ablation is conven-
tionally thought to be impractical, because transmuralventricular lesions are probably rare with the current
ablation technology. Endocardial substrate-based ablation
targeting delayed and fragmented local potentials has been
reported but never used while monitoring the epicardial
facing site. In this study, the multielectrode mapping
catheter placed epicardially was used, not only for high-
density mapping, but also as a landmark of the target
Epi-LAVA location, guiding the operator to the facing
endocardial site exactly. It also enables online monitoring of
the impact of endocardial ablation on Epi-LAVA.
Both low bipolar amplitude of the target Epi-LAVA and
low unipolar amplitude at the facing endocardial region were
strongly associated with the successful elimination of Epi-
LAVA transmurally. These ﬁndings might indicate that
transmural Epi-LAVA elimination is more feasible in re-
gions of wall thinning. Where Epi-LAVA are located
outside the wall thinning area, it seems to be difﬁcult to
penetrate deep enough into the myocardium to disrupt the
intramural or subepicardial circuits. We found that the
negative predictive value for elimination of Epi-LAVA
from the endocardium outside the LV wall thinning areas
was 100%. These ﬁndings allow the operator to avoid
ineffective RF energy applications on the endocardium. In
patients with NICM, Epi-LAVA elimination from the
facing endocardial site is more difﬁcult. This might be
explained by our ﬁnding of a lower proportion of Epi-
LAVA within the wall thinning segmentation in NICM
than in ICM. This ablation technique yields maximal
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1425beneﬁt in patients with ARVC. A prior study of in vivo
lesion assessment has demonstrated that transmural lesions
are more likely to be attained in the RVdnot unexpected,
because the ventricular wall here is thinner compared with
the LV (13).
Impact of elimination of endocardial LAVA on epicardial
substrate. Even if endocardial ablation cannot eliminate the
Epi-LAVA at the facing site transmurally, a subset of
epicardial scar had no LAVA anymore after complete elim-
ination of Endo-LAVA. The presence of Endo-LAVA was
signiﬁcantly associated with the impact of endocardial abla-
tion on Epi-LAVA, suggesting the presence of the inter-
connecting channels between endo- and epicardial LAVA
regions. This phenomenon is less common in NICM
compared with ICM. This is consistent with the known
characteristics of scar in different types of structural heart
disease; that is, arrhythmia substrates in NICM are located
predominantly intramurally or subepicardially with the min-
imal subendocardial substrate (3), whereas the ischemic scar
usually progresses from the subendocardium to the epicar-
dium within the territory of the culprit coronary arteries.
Clinical implications. Epicardial mapping and ablation
might conventionally be started directly before the endo-
cardial attempt if the epicardial substrate is thought to be
responsible for VT perpetuation. However, our ﬁndings
show that some epicardial ablations can be avoided if
endocardial ablation is performed ﬁrst. Elimination of
Epi-LAVA endocardially can diminish the need for
epicardial RF energy delivery, increasing the safety of abla-
tion. Furthermore, the present technique has the possibility
to improve the efﬁcacy of ablation, because it may eliminate
subepicardial surviving ﬁbers, which could have been
impossible to eradicate from the epicardium because of the
existence of epicardial fat and coronary vessels.
The present study provides a valuable clue suggesting the
anatomic and electrophysiological characteristics that pre-
dict the impact of endocardial ablation on epicardial
arrhythmia substrate modiﬁcation. This approach is less
useful if Epi-LAVA are located outside the LV wall thin-
ning area as imaged by contrast-enhanced MDCT, if there
is no substrate at the corresponding endocardial region, or if
the unipolar voltage of corresponding endocardial region is
normal. Also, it is less effective for substrate in NICM.
Further development of alternative approaches is warranted
to improve the efﬁcacy of ablation in these less favorable
situations.
Study limitations. Although this ablation technique was
performed in consecutive patients prospectively, RF pa-
rameters such as ablation time and power were not sys-
tematically standardized in each RF energy application for
the purpose of this study. Moreover, we did not deliver
higher-power or longer RF selectively at healthier regions
with normal voltage and nonthinned sites in an attempt to
make a deeper lesion. Although our data provided no
justiﬁcation for high-power output or prolonged ablation
delivery, we cannot rule out the possibility that this moreaggressive strategy might be associated with a higher rate of
Epi-LAVA elimination. However, extensive endocardial
ablation to get rid of Epi-LAVA might increase the risk for
complications such as volume overload, steam pop or cardiac
perforation, and thromboembolic events.Conclusions
Elimination of epicardial LAVA from endocardial ablation
is feasible and has maximum beneﬁt in patients with
ARVC and ischemic cardiomyopathy where the epicardial
substrate is located in a thin myocardial wall. This novel
approach has the potential to reduce or obviate the need for
epicardial RF energy delivery, and therefore could be per-
formed before epicardial ablation for the modiﬁcation of
epicardial arrhythmia substrate.
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APPENDIX
For a supplemental Methods section, please see the online version of this
article.
